Loading
A phase 2 trial of pembrolizumab, paclitaxel / nab-paclitaxel, carboplatin and olaparib in triple-negative breast cancer, run by Okayama University, now recruiting.
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT05485766 by Okayama University, with a registry enrolment figure of 23 participants, started 2024-07-16 and due to reach its primary completion in 2028-06-30. Interventions recorded: Pembrolizumab; Paclitaxel; Carboplatin; Olaparib; Definitive Surgery. Conditions listed: Triple Negative Breast Neoplasms; Triple Negative Breast Cancer; Breast Neoplasms; Breast Cancer; BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; BRCA-Associated Breast Carcinoma. Triple-negative eligibility wording from the registry: "* Have histologically confirmed TNBC, as defined by the most recent ASCO/CAP guidelines". Sites: Japan. No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.